You are here

Taltz

Novartis takes aim at Eli Lilly with Cosentyx FDA nod in spondyloarthritis

Novartis takes aim at Eli Lilly with Cosentyx FDA nod in spondyloarthritis

Fierce Pharma

spondyloarthritis

Flag link:

Eli Lilly's Taltz beats Novartis to the punch with FDA approval in spondyloarthritis

Eli Lilly's Taltz beats Novartis to the punch with FDA approval in spondyloarthritis

Fierce Pharma

axial spondyloarthritis

Flag link:

Eli Lilly's Taltz extends its head-to-head Humira beat with 52-week psoriatic arthritis data

Eli Lilly's Taltz extends its head-to-head Humira beat with 52-week psoriatic arthritis data

Fierce Pharma

psoriatic arthritis

Flag link:

Lilly counts on growing markets to boost lagging Taltz, Trulicity

Lilly counts on growing markets to boost lagging Taltz, Trulicity

Fierce Pharma

type 2 diabetes

Flag link:

Lilly's Taltz wins third approval, this time in patients with active ankylosing spondylitis

Lilly's Taltz wins third approval, this time in patients with active ankylosing spondylitis

Endpoints

monoclonal antibodies

ankylosing spondylitis

Flag link:

Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt

Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt

Fierce Pharma

Flag link:

Lilly’s Taltz scrapes win against Humira in psoriatic arthritis

Lilly’s Taltz scrapes win against Humira in psoriatic arthritis

Pharmaforum

psoriatic arthritis

Flag link:

Eli Lilly's Taltz touts long-term clear skin data after unimpressive first-quarter sales

Eli Lilly's Taltz touts long-term clear skin data after unimpressive first-quarter sales

Fierce Pharma

Flag link:

Eli Lilly Falls Despite Positive Phase 3 Results From Taltz Study

Eli Lilly Falls Despite Positive Phase 3 Results From Taltz Study

TheStreet.com

axial spondyloarthritis

clinical trials

Flag link:

Johnson & Johnson keeps the heat on Tremfya's rivals with at-home injector nod

Johnson & Johnson keeps the heat on Tremfya's rivals with at-home injector nod

Fierce Pharma

Flag link:

Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial

Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial

Reuters

psoriatic arthritis

clinical trials

Flag link:

Eli Lilly Updates Spondyloarthritis Trial Data and Long-Term Rheumatoid Arthritis Studies

Eli Lilly Updates Spondyloarthritis Trial Data and Long-Term Rheumatoid Arthritis Studies

BioSpace

Flag link:

Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis in heated immunology race

Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis in heated immunology race

Endpoints

ankylosing spondylitis

Flag link:

Eli Lilly Builds Case to Expand Immune Drug’s Use to Spinal Arthritis

Eli Lilly Builds Case to Expand Immune Drug’s Use to Spinal Arthritis

Xconomy

Flag link:

Eli Lilly touts PhIII success for Taltz as rival Novartis stays well out front in crowded immunology race

Eli Lilly touts PhIII success for Taltz as rival Novartis stays well out front in crowded immunology race

Endpoints

ankylosing spondylitis

Flag link:

Lilly's 2018 forecast beats on strength of new drugs

Lilly's 2018 forecast beats on strength of new drugs

Yahoo/Reuters

Flag link:

Lilly's Taltz takes Cosentyx rivalry into psoriatic arthritis with new FDA nod

Lilly's Taltz takes Cosentyx rivalry into psoriatic arthritis with new FDA nod

Fierce Pharma

psoriatic arthritis

Flag link:

Humira may spend most on TV, but Xeljanz, Taltz and Breo notch highest view rates

Humira may spend most on TV, but Xeljanz, Taltz and Breo notch highest view rates

Fierce Pharma

Flag link:

Novartis star Cosentyx, facing new rivals, may gain edge as a disease-modifying med

Novartis star Cosentyx, facing new rivals, may gain edge as a disease-modifying med

Fierce Pharma

Valeant Pharmaceuticals

Flag link:

Are DTC ads tipping the balance in psoriasis battle between Lilly’s Taltz and Novartis’ Cosentyx?

Are DTC ads tipping the balance in psoriasis battle between Lilly’s Taltz and Novartis’ Cosentyx?

Fierce Pharma

DTC advertising

Flag link:

Pages